Table 2.

Characteristics of 5-year survivors

Pt	Primary histology	Dx - CPI (months)	M stage	First CPI	PFS (months)	Subsequent systemic Rx	Local	Regional	OS (months)	Vital status
1	Acral	34	M1a	CTLA-4	4	PD-1, chemo, trial	None	ILP	90	DOD
2	Acral	14	M1a	CTLA-4	8	PD-1, sorafenib	SRS, surg, SBRT	RT	79 +	NED
3	Mucosal	4	M1c	CTLA-4+PD-1	38 CR	CTLA-4+PD-1	None	None	99+	NED
4	Mucosal	37	M1c	CTLA-4+PD-1	18	None	Surg, SBRT	RT	71+	NED
5	Mucosal	13	M1b	CTLA-4+PD-1	6	None	SRS, surg	None	79+	NED
6	Mucosal	37	M1a	CTLA-4+PD-1	35	ACT, BRAF-i	Surg	None	82	DOD
7	Uveal	22	M1c	CTLA-4	80 CR+	PD-1*	None	None	80+	NED
8	Uveal	167	M1c	CTLA-4	6	PD-1	SRS, surg	RT	62+	NED
9	Uveal	44	M1c	CTLA-4	15	PD-1	SRS	ChEmb, RT	67	DOD
10	Uveal	199	M1c	CTLA-4	42 CR	PD-1, trial	None	None	90+	AWD

Ten patients with 5-year survival are shown. Dx-CPI indicates the time interval between initial diagnosis and first treatment with CPI. ‘+’ indicates ongoing CR or survival.

*Denotes a patient with stable disease who was started on anti-PD-1 before progression occurred.

AWD, alive with disease; ChEmb, hepatic chemoembolization; CPI, checkpoint inhibitor; CR, complete response; CTLA-4, cytotoxic T lymphocyte-associated antigen 4; DOD, died of disease; Dx, Diagnosis; ILP, isolated limb perfusion; NED, no evidence of disease; OS, overall survival; PD-1, programmed death 1 receptor; PFS, progression-free survival; RT, wide-field radiation therapy; Rx, treatment; SBRT, stereotactic body radiotherapy to extracranial metastases; SRS, stereotactic radiosurgery for central nervous system metastases; Surg, surgery.